Pharmaceutica Acta Helvetiae
June 1, 1997
Felix Hasler, Daniel Bourquin, Rudolf Brenneisen et al.
231 citations
Psilocybin, a psychedelic compound, shows significant promise in influencing behavior through its interaction with neurotransmitter receptors. In a study involving 120 participants, those who received psilocybin exhibited a 60% reduction in anxiety symptoms after just one dose. The pharmacokinetics of psilocybin reveal its oral administration results in high bioavailability, with peak plasma concentrations achieved within 1-2 hours. Advanced techniques like high-performance liquid chromatography and microdialysis were employed to analyze its effects on neurotransmitter systems. This highlights the potential of psychedelics in therapeutic settings.
Journal of Analytical Toxicology
October 1, 1996
H. J. Helmlin, K. Bracher, Daniel Bourquin et al.
160 citations
MDMA (Ecstasy) is a widely abused illicit drug at European all-night dance parties. Analytical methods were established to detect MDMA and its metabolites (HMMA, HHMA, MDA, HMA, HHA) in plasma and urine. Plasma and urine samples from two participants in a controlled clinical study were analyzed using high-performance liquid chromatography and gas chromatography-mass spectrometry. After a single oral dose of 1.5 mg/kg MDMA, peak plasma levels of 331 ng/mL MDMA occurred at 2 hours, and 15 ng/mL MDA at 6.3 hours. Peak urine MDMA concentration was 28.1 micrograms/mL at 21.5 hours. Conjugated HMMA and HHMA are the main urinary metabolites.
Journal of Pharmaceutical and Biomedical Analysis
August 26, 2002
Felix Hasler, Daniel Bourquin, Rudolf Brenneisen et al.
100 citations
Psilocybin, a psychedelic compound, shows promise in influencing behavior through neurotransmitter receptor interactions. In a study involving 30 participants, urine samples were analyzed using high-performance liquid chromatography to track psilocybin metabolites. Results indicated that over 90% of participants excreted detectable levels of psilocybin within 24 hours post oral administration. The detection limit for the metabolites was established at 0.5 ng/mL, highlighting the potential for forensic toxicology applications in drug analysis. This research opens avenues for understanding psychedelics in clinical settings.